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The antiglycemic drug metformin, widely prescribed as first-line
treatment of type II diabetes mellitus, has lifespan-extending
properties. Precisely how this is achieved remains unclear. Via
a quantitative proteomics approach using the model organism
Caenorhabditis elegans, we gained molecular understanding of
the physiological changes elicited by metformin exposure, includ-
ing changes in branched-chain amino acid catabolism and cuticle
maintenance. We show that metformin extends lifespan through
the process of mitohormesis and propose a signaling cascade in
which metformin-induced production of reactive oxygen species
increases overall life expectancy. We further address an important
issue in aging research, wherein so far, the key molecular link that
translates the reactive oxygen species signal into a prolongevity
cue remained elusive. We show that this beneficial signal of the
mitohormetic pathway is propagated by the peroxiredoxin PRDX-2.
Because of its evolutionary conservation, peroxiredoxin signaling
might underlie a general principle of prolongevity signaling.
Metformin, an antiglycemic biguanide drug and the mostcommon treatment of type II diabetes mellitus, has life-
extending capabilities (1, 2). Several other human diseases, such
as cancer (3) and nonalcoholic fatty liver disease (4), are also
potentially alleviated by metformin treatment. This suggests
that metformin acts on common pathways involved in a spec-
trum of aging-related disorders. Because of its demonstrated
beneficial effect on lifespan in the nematode Caenorhabditis
elegans (5, 6) and in the rodents Rattus norvegicus (1) and Mus
musculus (2), these models facilitate research into the underlying
mode of action.
It has been hypothesized that metformin elicits its beneficial
effects by mimicking dietary restriction (DR) (7), a regimen
wherein a physiological response is triggered by reducing the
uptake of nutritive calories. The physiological response to DR
causes lifespan extension and delays age-dependent decline from
yeast to primates (8). The idea of similarity sprouts from the
observed low blood glucose and insulin levels combined with
increased glucose utilization in both calorically restricted and
metformin-treated animals (7). In addition, metformin-treated
worms show phenotypes similar to DR worms (5), and tran-
script profiles of metformin-treated and DR mice also overlap
significantly (9).
Caution is due, however, in referring to DR, because different
methods to induce DR in C. elegans act through different genes
to elicit corresponding effects on lifespan (10–12). Glucose re-
striction, a specific type of DR, requires AMP-dependent kinase
(AMPK) to extend lifespan. Activation of AMPK leads to in-
creased mitochondrial production of reactive oxygen species
(ROS), which induces stress defense and results in a net increase
in longevity. This process of lifespan extension based on mito-
chondrial oxidative stress is known as mitohormesis (13).
Despite its similarities to DR and its widespread use as an
antiglycemic drug, the actual mode of action of metformin is
largely unknown and a subject of much debate. In mammals,
metformin is generally believed to act through the activation of
AMPK, one of the main regulators of cellular energy homeo-
stasis (2, 14–16), but recent research suggests the existence of
AMPK-independent mechanisms as well (17, 18). More up-
stream, metformin is thought to activate AMPK through partial
inhibition of complex I of the electron transport chain (ETC)
and a resultant increase in the AMP/ATP ratio (19–21), although
again, not all data support this theory (16, 22). Important players
in metformin-induced lifespan extension in C. elegans are the
liver kinase B1 ortholog PAR-4, the AMPK ortholog AMP-
activated kinase-2 (AAK-2), and the skinhead-1 (SKN-1) tran-
scription factor, which is involved in activating phase II de-
toxification mechanisms (5). It has recently been demonstrated
that in C. elegans, metformin partly elicits its effects through
altering the folate metabolism of its microbial food source (6),
but questions about its direct effects are largely unaddressed. It
is, for instance, unclear how metformin induces AAK-2 and
SKN-1 activity. Overall, many gaps remain in our knowledge of
metformin-induced lifespan extension.
To study the targets of metformin, we performed a proteomic
analysis on metformin-treated C. elegans and used the results as
a framework for follow-up experiments. We observed striking
similarities between metformin-treated and glucose-restricted
worms and discovered several factors involved in mitohormetic
regulation of lifespan, including a previously unidentified role for
peroxiredoxin-2 (PRDX-2), which seems to be responsible for
translating oxidative stress into a downstream prolongevity sig-
nal. In addition to lifespan extension, we also report features that
contribute to the healthspan of metformin-treated worms.
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Results
Molecular Changes in Caenorhabditis elegans upon Metformin Exposure:
A Proteomic Approach. To gain a deeper understanding of the
physiological changes elicited by metformin exposure, a differen-
tial gel-based proteomics experiment was performed. A total of
164 spots with differential abundances were detected, 134 of which
could be identified by mass spectrometry. After removal of du-
plicate identifications, the final analysis resulted in a list of 58 up-
regulated and 30 down-regulated proteins (Dataset S1).
Enrichment analysis (23) of the up-regulated proteins resulted
in the detection of several overrepresented pathways (Table 1),
of which the branched-chain amino acid (BCAA) degradation
pathway was most markedly enriched. All other enriched path-
ways, including glycolysis and the tricarboxylic acid (TCA) cycle,
are involved in general energy metabolism. No significant path-
way enrichment was observed in the analysis of down-regulated
proteins. Combined analysis of all differential proteins (both up
and down) did not reveal additional pathways of interest.
Further functional clustering was used to subdivide the up-
and down-regulated proteins into meaningful groups (Table 1).
For each functional cluster detailed information, including sub-
terms and proteins in each group, was gathered to assist in data
interpretation (Dataset S1). These results were used as the
backbone of hypothesis-driven experiments into the mechanisms
induced by metformin treatment.
Metformin Does Not Induce Mitochondrial Protein Unfolding Stress.
Because of the marked clustering of mitochondrial proteins
(Table 1) and metformin’s putative inhibitory effect on complex I
of the ETC, it needs to be tested whether metformin is capable
of inducing the mitochondria-specific unfolded protein response
(UPRmt). This is essential because the UPRmt increases lifespan
in response to either misfolding of mitochondrial proteins or
stoichiometric abnormalities in the ETC complexes (24).
We did not observe up-regulation of the UPRmt marker hsp-6
in worms exposed to metformin (Fig. 1). Additional experiments
with higher concentrations of metformin and different exposure
times yielded similar negative results (Fig. S1). As such, lifespan
extension of metformin via the induction of the UPRmt is un-
likely, which suggests that the drug affects the mitochondria in
another way.
Metformin Increases Lifespan Through Hormetic Phenomena. Met-
formin has been put forward as a possible DR mimetic (7), and
because DR has been linked to mitohormesis (13, 25), we looked
into evidence for a role for mitohormesis in metformin-induced
lifespan extension. Clustering analysis of the proteomics experi-
ments revealed a significant overrepresentation of several mi-
tochondrial proteins and proteins involved in catabolism (Table 1).
These clusters might point to an increase in respiration, one of
the hallmarks of mitohormesis (13). Indeed, upon metformin
treatment, we observed a significant increase in respiration (45%)
and metabolic heat production (38%) (Fig. 2A) in wild-type worms.
These changes, in combination with the AMPK-dependence of
metformin-mediated longevity (5), strongly resemble the mito-
hormetic pathway (13) and might point toward an increase in
ROS production.
To verify whether mitochondrial ROS production was affected
by metformin treatment, we measured hydrogen peroxide levels
in metformin-treated worms. ROS production was indeed in-
creased (Fig. 2B), further supporting the mitohormesis hypoth-
esis. Induction of ROS production was already clear after 24 h
of exposure to metformin (Fig. 2B). This increase in ROS seems
to be an integral part of metformin-induced lifespan extension,
because treatment with the potent antioxidants N-acetylcysteine
(NAC) (13) and butylated hydroxyanisole (BHA) (26) abol-
ished the positive effect of metformin on lifespan (Fig. 2C and
Table 1. Functional analysis of differential proteins
Pathway or cluster affected by metformin Significance value
Pathway enrichment of up-regulated proteins*
Pathway P value
Valine, leucine, and isoleucine degradation 9.85E-09
Citrate cycle (TCA cycle) 1.38E-04
Glycolysis/gluconeogenesis 2.47E-04
Pyruvate metabolism 4.62E-04
Functional clustering of up-regulated proteins†
Cluster Enrichment score
Mitochondrial 6.86
Carbohydrate metabolic processes 5.78
Cytoskeleton 4.28
Mitochondrial lumen 4.20
FAD binding and reduction 3.70
Biotin/lipoyl attachment 3.02
Nucleoside binding 3.01
Catabolic processes 2.66
Longevity/aging 2.46
Muscle component 2.39
Catabolism and respiration 2.07
NAD binding and reduction 1.99
Cytoskeleton organization 1.39
Functional clustering of down-regulated proteins†
Cluster Enrichment score
Vitellogenins/reproduction 3.20
Mitochondrial 2.68
Galectins 2.07
Longevity/aging 1.59
Biosynthetic processes (DNA/RNA) 1.39
Functional analysis of the differential proteomics data. All enrichment
analyses were performed using the Database for Annotation, Visualization
and Integrated Discovery (DAVID) (23).
*Kyoto Encyclopedia of Genes and Genomes pathways overrepresented (P <
0.05) in the group of proteins up-regulated after metformin treatment.
†Functional clustering of proteins, which are significantly altered after met-
formin treatment. The reported enrichment score was calculated by DAVID
according to the Fisher exact score of each clustered term. The higher the value,
the more enriched the cluster. Only clusters with an enrichment score higher
than 1 were reported. Complete information can be found in Dataset S1.
Fig. 1. Metformin treatment does not induce the mitochondria-specific
unfolded protein response (UPRmt). Day-1 adult metformin-treated hsp-6::GFP
worms show no difference in fluorescence compared with untreated control
worms. hsp-6::GFP worms were exposed to cco-1 RNAi as a positive control.
cco-1 encodes a cytochrome c oxidase subunit, an integral part of the mi-
tochondrial electron transport chain (24).
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Fig. S2A). Finally, the critical phase for metformin-mediated
lifespan extension clearly resembles the critical phase for other
mitohormetic stressors (13), because treatment with metformin
starting from adulthood onward or during the first few days
of adulthood only were sufficient to increase lifespan. This
is opposed to treatment with metformin during larval de-
velopment only, which had no detectable effect on lifespan
(Fig. S2B).
Metformin-Mediated Lifespan Extension Requires the Peroxiredoxin
PRDX-2. The mitohormetic pathway as seen during glucose re-
striction is induced when low availability of glucose causes low
energy levels, which in turn activates AMPK (13). AMPK activity
increases catabolism and respiration, which results in the in-
creased production of ROS and a resultant activation of hor-
metic protective mechanisms (13). The largest hiatus in this
pathway is the step between the increased ROS production and
the induction of stress defense: no molecule was put forward that
might translate the ROS signal into further downstream defense.
We therefore set out to reveal this missing link and to further
complete the hormetic signaling pathway.
Peroxiredoxins are known hydrogen peroxide scavengers, and
their oxidized dimeric form is involved in the direct activation
of kinases in mammalian cells (27). Because the peroxiredoxin
PRDX-2 was up-regulated during metformin treatment (Dataset
S1), this protein is of particular interest as a potential inductor of
mitohormesis. Deletion of the prdx-2 gene results in an extreme
decrease in lifespan upon metformin treatment (Fig. 2D). Not
only did the positive effect of metformin on lifespan disappear,
the prdx-2 experimental group collapsed when exposed to met-
formin. Treatment with NAC partially rescued this deleterious
effect, implying that excessive ROS production is at least partly
responsible for the detrimental effect of metformin on these
mutants (Fig. S2C). In support of these results, we observed
increased formation of PRDX-2 dimers after metformin treat-
ment (Fig. 2E and Fig. S3). Because these oxidized dimers are
likely involved in cellular signaling (27), we propose that PRDX-2
induces prolongevity signaling during the mitohormetic response
to metformin treatment.
One of the potential downstream targets of PRDX-2 is the p38
MAP kinase family-1 (PMK-1) protein, which is involved in the
activation of the SKN-1 transcription factor (28). This tran-
scription factor is in turn required for metformin-mediated
longevity (5). Western blot analysis revealed a marked increase
in phosphorylation of PMK-1 after metformin treatment. In
contrast, deletion of prdx-2 resulted in an absence of metfor-
min-induced phosphorylation of PMK-1 (Fig. 2F). These data
strongly imply that PRDX-2 is required for PMK-1 activation
after metformin treatment.
In sum, all these findings subscribe that metformin extends
lifespan via mitohormesis in C. elegans and that PRDX-2 is an
integral part of the mitohormetic pathway.
Metformin Inhibits Complex I of the ETC. Metformin is generally
believed to act through inhibition of complex I of the ETC (19–21),
although some recent findings cast doubt on this (16, 22).
Treatment of C. elegans with rotenone, another complex I
inhibitor, at a concentration that extends longevity, results in
a decrease in total oxygen consumption (25). Our finding that
metformin increases respiration in worms therefore raises the
question of whether it is truly capable of inhibiting complex I of
the ETC.
We tested whether metformin is able to affect electron flow in
mitochondria extracted from C. elegans and observed a clear and
specific inhibition of electron flow from complex I, whereas the
electron flow from complex II was unaffected (Fig. 3A and Fig.
S4 A and B). These results, clearly mimicking the inhibitory ac-
tion of rotenone (Fig. S4A), complement our previous data only
if metformin inhibits complex I in a distinct way. To this end, we
tested whether metformin and rotenone had different effects on
ROS production in mitochondria. At concentrations at which
both completely inhibit complex I respiration and after feeding
only complex I, metformin increased ROS production, whereas
rotenone decreased it (Fig. 3B), implying a fundamental differ-
ence between rotenone’s and metformin’s inhibitory action on
complex I.
The BCAA Degradation Pathway Is Up-Regulated During Metformin
Treatment. The BCAAs leucine, isoleucine, and valine display
a certain duality in relation to health and longevity. On one hand
Fig. 2. Metformin increases lifespan according to the principle of mito-
hormesis, for which it requires PRDX-2. (A) Metformin treatment increases
metabolic heat production (**P < 0.01; n = 3 for untreated and n = 4 for
treated worms) and respiration (*P < 0.05; n = 3). Bars represent mean ±
SEM. (B) Metformin induced a significant increase in H2O2 release in day-1
adult worms after both continuous exposure during development (*P < 0.05;
n = 7) and after 24 h of exposure, starting from the young adult stage (*P <
0.05; n = 7 for untreated and n = 5 for treated worms). Exposing the worms
for 4 h before measurement did not result in a significant increase (n.s.P >
0.05; n = 7). Bars represent mean ± SEM. (C) The antioxidant NAC abolishes
the lifespan-extending effect of metformin (***P < 0.001; n ≥ 169 for each
curve; Table S1). (D) prdx-2 is required for metformin-induced lifespan ex-
tension. Metformin treatment significantly reduces lifespan of prdx-2
mutants (***P < 0.001; n ≥ 127 for each curve; Table S1). (E) Metformin
treatment promotes the formation of PRDX-2 disulfide dimers (**P < 0.01),
implied to function in signal transduction. Bars represent mean ± SEM (n = 4).
(F ) PRDX-2 is required for metformin-induced phosphorylation of the p38
MAP kinase PMK-1. Metformin treatment of wild-type worms induced
phosphorylation of PMK-1, inferred from a larger band observed on the
Western blot. This metformin-mediated induction of PMK-1 phosphory-
lation is absent in prdx-2 knockout worms. Histone H3 levels were used as
a loading control.
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their effectiveness has been noted in the treatment of liver and
cardiac diseases (29, 30), and up-regulation of BCAAs is one of
the metabolic signatures of the long-lived daf-2 mutant (31, 32).
On the other hand, BCAAs have also been causally linked to the
development of insulin resistance, type II diabetes (33), and
neuropathologies (34). We set out to confirm the marked up-
regulation of the BCAA degradation pathway (Table 1 and Fig.
S5) at the level of free BCAAs in metformin-treated worms.
Metformin treatment resulted in a significant decrease (−55%)
in the amount of free BCAAs, lending further support to the
validity of the proteomics data (Fig. 4A).
Metabolic Flux During Metformin Treatment.One of the most striking
properties of metformin as an antidiabetic in humans is its ability
to cause weight loss in patients through, among others, activation
of the β-oxidation pathway (2, 35, 36). We observed a 4.3-fold up-
regulation of mitochondrial acyl-CoA dehydrogenase-1 (ACDH-1)
after metformin treatment (Dataset S1), defining it as the stron-
gest up-regulated protein by a margin. Acyl-CoA dehydrogenases
catalyze the first step in the β-oxidation of fatty acids.
We questioned whether the shift in β-oxidation suggested by
ACDH-1 induction truly occurs and whether it is involved in
metformin-induced lifespan extension. If so, we would grossly
expect overall fat levels to drop in treated worms. Measuring
fat content in L4 worms, we found evidence for increased
β-oxidation because metformin-treated worms showed signifi-
cantly lower (−11.4%) fat stores (Fig. 4B). A similar reduction in
fat content was found in metformin-treated C. elegans using dif-
ferent methods (5).
To our surprise, acdh-1 knockout worms showed an even
stronger metformin-induced lifespan extension than wild-type
worms (Fig. 4C). This implies a more complex interaction be-
tween β-oxidation and metformin (Discussion).
Metformin-Treated Worms Attenuate Age-Related Morphological
Decline. Aging worms start to show several morphological defects
(37) and shrink in size (38), but metformin-treated worms
seemed less affected by this phenomenon. After measuring
several formalin-fixed worms of various ages (Fig. 5A) it be-
came clear that nontreated worms started losing volume after
day 6 of adulthood, whereas metformin-treated worms still
Fig. 3. Metformin inhibits complex I of the ETC in a way distinct from rotenone. (A) Metformin inhibits complex I- but not complex II-based respiration.
Higher values for O2 flux indicate higher respiration, negative values indicate a small influx of O2, usually due to the injection of a compound. The effect of
metformin on mitochondrial respiration was measured by sequentially adding compounds to stimulate different parts of the ETC. Green arrows indicate
compounds that were added in both the control and metformin-treated cells; red arrows indicate compounds that were only added in the treated cell. After
adding an equal volume of mitochondria (↓start), metformin was added to one of the cells (↓metformin). Subsequently, the complex I substrates pyruvate and
malate (↓P+M) were added, followed by the addition of ADP (↓ADP), initiating electron transport from complex I. Metformin-treated mitochondria clearly fail
to initiate complex I-based respiration, thus indicating that metformin inhibits electron transport from complex I in vitro. Finally, the complex II substrate
succinate (↓S) was added to the metformin-treated cell, which led to a marked increase in mitochondrial respiration, indicating that metformin does not block
electron transport from complex II. Two variations of this experiment were executed to also use the potent complex I inhibitor rotenone as a positive control
(Fig. S4A) and to add succinate to the negative control condition as well (Fig. S4B). (B) Mitochondria treated with metformin produce H2O2 at a higher rate
than untreated mitochondria (***P < 0.001; n = 3). Treatment with the complex I inhibitor rotenone had the opposite effect (***P < 0.001; n = 3).
Fig. 4. Metformin induces the BCAA degradation and β-oxidation pathways but the β-oxidation enzyme ACDH-1 is not required for metformin-mediated
longevity. (A) Metformin treatment stimulates the BCAA degradation pathway (Fig. S5) and in turn reduces the concentration of free BCAAs in C. elegans
(**P < 0.01). Bars represent mean ± SEM (n = 6). (B) Metformin-treated worms show reduced fat storage (***P < 0.001; n = 30 for untreated and n = 33 for
treated worms), possibly indicating increased flux through the β-oxidation pathway. Bars represent mean ± SEM. (C) Deletion of β-oxidation enzyme acdh-1
results in a proportionally larger effect of metformin on longevity (***P < 0.001; n ≥ 54 for each curve; Table S1).
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retained their normal volume on day 9. Although long-lived
mutants are often smaller than their wild-type siblings (39),
our results fit the recent observations that within isogenic
populations the larger animals are generally the longer-lived
ones (38).
Muscle and cuticle are known to show severe morphological
defects with increasing age in C. elegans (37), making them prime
targets to question whether these tissues are better maintained in
metformin-treated worms. Our proteomics data already pointed
to an increase in muscle mass and several changes in the cyto-
skeleton (Table 1), including up-regulation of intermediate fil-
ament proteins (Dataset S1). Electron micrographs of 9-d-old
control and metformin-treated worms displayed no difference
in body wall muscle volume, but there was a clear difference
in cuticle morphology (Fig. 5 B and C). Whereas the cuticle of
9-d-old adult nontreated worms started showing signs of age-
related “wrinkling” and disorganization, the cuticle of metformin-
treated worms resembled that of a young animal. Considering the
cuticle’s known role in maintaining the shape and size of nema-
todes (40), it can be assumed that it is this amelioration of cuticle
deterioration that allows metformin-treated worms to retain a
healthy, young morphology.
Discussion
We profiled the effect of metformin in C. elegans using a differ-
ential proteomics approach and used the resulting data for fur-
ther examination of its beneficial effects and mode of action.
We observed many changes in the mitochondrial proteome,
which might point toward mitonuclear protein imbalance (41)
and an altered mitochondrial metabolism. It is therefore prob-
able for metformin to increase lifespan through both the process
of mitohormesis and the induction of the UPRmt. However,
metformin administration during the larval stages had no effect
on lifespan, whereas the critical phase for UPRmt induction in
C. elegans is during larval development (24, 42). Because met-
formin also proved unable to induce the UPRmt, it is not a
likely in vivo contributor to lifespan extension by metformin
in C. elegans. Contrary to the UPRmt, the mitohormetic pathway
is important for metformin-mediated longevity in this worm.
Hormesis in aging is defined as the process by which a short-
term and nonlethal stressor induces the stress response mecha-
nisms of an organism and thereby increases stress resistance and
overall life expectancy (43). The mitohormetic pathway, first
described in glucose-restricted C. elegans (13), states that a low
availability of ATP—due to low glycolytic activity—causes acti-
vation of AMPK. AMPK in turn promotes general catabolism
and mitochondrial respiration, leading to increased production
of ROS (the hormetic “stressor”), which subsequently act as
messengers to activate further stress defenses, prolonging life-
span. This contradicts the classic oxidative stress theory of aging,
which postulates that ROS, because of their ability to damage
biomolecules, would be the causative factor of aging (44). We
were able to fully reproduce the mitohormetic phenomenon in
metformin-treated worms and showed that metformin increases
respiration, metabolic heat production, and ROS generation in
C. elegans. Inhibition of ROS signaling abolishes the lifespan-
extending effects of metformin, proving that metformin-medi-
ated lifespan extension is dependent on the mitohormetic
pathway and most closely resembles the C. elegans response
to glucose restriction.
Although well studied, some major missing links remained in
the mitohormetic pathway, in particular how the ROS signal can
be translated to increased lifespan. We were able to demonstrate
that the C. elegans peroxiredoxin PRDX-2, previously shown to
be involved in peroxide and heavy metal resistance (45), is of
major importance to this function. Peroxiredoxins are a class of
antioxidant proteins characterized by their high susceptibility to
cysteine oxidation (46, 47). PRDX-2 is a typical 2-Cys peroxi-
redoxin (45), of which the active, oxidized form exists as a homo-
dimer (48). It has recently been shown that these dimers are
subsequently able to oxidize and activate specific substrates, such
as the MAP kinase ASK1 (27), thus resolving how these proteins
might be able to translate ROS signals into downstream signaling.
In the same vein, our experiments revealed increased formation of
PRDX-2 dimers after metformin treatment. These oxidized di-
mers might activate ASK1’s closest ortholog in C. elegans, the
MAP kinase NSY-1, which functions upstream in the same sig-
naling pathway as the MAP kinases SEK-1 and PMK-1 (49). This
evolutionarily conserved MAP kinase cascade could ultimately
activate several downstream targets that mediate stress de-
fense, including SKN-1 (28). We showed that prdx-2 is re-
quired for the downstream activation of PMK-1 in response to
metformin exposure, completing the pathway (Fig. 6). Therefore,
PRDX-2 may well be the protein responsible for translating oxi-
dative stress into longer lifespan in C. elegans. Because the lon-
gevity-promoting effect of exercise in humans also depends on ROS
signaling (50), this pathway may be evolutionarily conserved.
AMPK activation is one of the main factors involved in
mitohormetic lifespan extension (13, 26). Although metformin is
known to activate AMPK, exactly how this occurs remains elu-
sive. The most common hypothesis is that metformin is able to
partially inhibit complex I of the mitochondrial ETC, which in
turn would lead to energy depletion and activation of AMPK
(19–21). Recently this has been debated (16, 22). One of the
main arguments against metformin-mediated inhibition of com-
plex I is the increased activity of pathways that generate energy
after metformin treatment. All these pathways require NAD+ to
function, and without efficient recycling of NADH to NAD+,
Fig. 5. Metformin attenuates the morphological decline with aging in C. elegans. (A) Metformin-treated worms retain a stable volume, whereas control worms
older than 6 d start shrinking. (B) Electron micrograph of the cuticle of a day-9 adult nontreated wild-type worm. Some deformations of the cuticle (seen as
“wrinkling,” marked with an arrow) are starting to manifest. (C) No structural abnormalities can be seen in a metformin-treated day-9 wild-type adult.
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these pathways are limited in activity. Because NADH is mainly
recycled at complex I of the ETC, blocking complex I should lead
to an increased NADH/NAD+ ratio and lower catabolism (Fig.
6). As a case in point, the complex I inhibitor rotenone indeed
increases the NADH/NAD+ ratio (51) and lowers the activity of
the β-oxidation pathway (16). We were able to show that met-
formin specifically inhibits complex I of the ETC in vitro, albeit
in a way that seems fundamentally distinct from rotenone: met-
formin increased mitochondrial ROS production, whereas rote-
none decreased it. High concentrations of rotenone reduce the
number of electrons that are transferred from NADH to com-
plex I (high NADH/NAD+ ratio), hence less electrons can leak
out to form ROS. Our results imply that upon metformin treat-
ment, NADH is still able to transfer its electrons, but these are
subsequently lost, resulting in increased ROS production (Fig. 6).
On the basis of these data, we suggest that metformin activates
AMPK through inhibition of complex I (Fig. S6), which leads to
an increase in respiration and a concomitant up-regulation of
several catabolic pathways (e.g., β-oxidation, glycolysis, BCAA
catabolism, and others) to provide the necessary substrate for the
ETC. Likely exacerbated by metformin-mediated perturbation of
electron transport, the increase in respiration ultimately leads to
a mitohormetic increase in ROS production in vivo (Fig. 6). Be-
cause elevated respiration under physiologically normal conditions
often leads to a reduction in ROS production (31), this indeed
implies a direct involvement of metformin in the observed in-
crease in ROS.
Treatment of C. elegans with metformin results in an overall
up-regulation of several pathways and processes (including gly-
colysis and the TCA cycle), most of which are involved in ca-
tabolism, supporting the shift toward increased respiration. Two
catabolic pathways stood out after metformin treatment: β-oxida-
tion, through the short chain acyl-CoA dehydrogenase ACDH-1,
and BCAA degradation. In light of metformin’s inhibitory action
on complex I but not complex II of the ETC, the observed in-
crease in β-oxidation seems a logical adaptation because it pro-
duces a relatively high amount of the complex II substrate
FADH2 compared with other catabolic pathways. This might
explain why knocking out acdh-1 adds to the lifespan increase
induced by metformin: high activity of the β-oxidation pathway
could temporarily increase ATP levels and inactivate AMPK
(Fig. 6 and Fig. S6). As such, deletion of acdh-1 could cause
a more stringent activation of the mitohormetic pathway. Fur-
ther experiments will be needed to fully explore the role of
β-oxidation in metformin-induced lifespan extension. Our results
suggest that the metformin-mediated increase in β-oxidation is
likely a compensatory mechanism that is unrelated to metformin-
induced longevity.
As for the BCAA degradation pathway, no clear singular
correlation between BCAAs and longevity has yet been found in
any organism. Although some evidence points toward BCAAs as
a metabolic signature of long life in C. elegans insulin receptor
mutants (31, 32), other studies have causally linked BCAAs to
the development of insulin resistance, diabetes (33), and neu-
ropathologies (34). Interestingly, BCAAs, leucine in particular,
are potent activators of the target of rapamycin (TOR) kinase.
Leucine deprivation has previously been associated with reduced
TOR signaling (52), which can in turn prolong lifespan and is
required for DR-mediated lifespan extension (53). However, it
remains unclear whether the drop in BCAA levels is necessary
for metformin-induced lifespan extension. The reduction in
BCAA concentration might result in lower RNA translation
into protein, both through inactivation of TOR and a reduction
in the amount of substrate necessary for translation (Fig. S6).
This in turn may lead to an increase in longevity. There is some
precedence for this hypothesis: amino acid imbalance has been
associated with increased longevity in Drosophila melanogaster (54),
among others (55). The recently described bacteria-specific ef-
fect of metformin on longevity in C. elegans (6) might similarly
depend on an amino acid imbalance that occurs through the
lowered production of methionine in metformin-treated bacteria
(Fig. S6). Our results suggest a hitherto unexplored role for the
BCAA degradation pathway in longevity.
Metformin not only increases lifespan but also healthspan of
C. elegans: treated worms retain a youthful morphology for a longer
time. How metformin is able to attenuate morphological decline
of the cuticle in C. elegans remains elusive, but the intermediate
filament protein IFC-2 (up-regulated after metformin treatment;
Dataset S1) seems particularly promising because it is required
for normal body shape and cuticle strength (56). Integrity of the
cuticle and epidermis might play a more important role in lon-
gevity than is generally thought. Deterioration in cuticle struc-
ture leads to a loss in barrier function, which may be one of the
causes of death of older nematodes (37, 40).
In conclusion, this work reveals insights in the process of
aging and shows that metformin extends lifespan through
mitohormesis. A missing link in the mitohormesis pathway in
C. elegans has now been assigned: the peroxiredoxin PRDX-2,
a protein that translates a ROS signal into a prolongevity cue.
Because peroxiredoxin signaling is evolutionarily conserved (27),
peroxiredoxins might hold a similar function in humans.
Materials and Methods
C. elegans Strains. The following strains were obtained from the Caeno-
rhabditis Genetics Center (University of Minnesota): wild-type N2, VC289
prdx-2(gk169), VC1011 acdh-1(ok1489), and SJ4100 zcIs13[hsp-6::GFP].
GA507 glp-4(bn2ts) daf-16(mgDf50) was provided by the Gems laboratory.
Strains were cultivated on standard nematode growth medium (NGM)
seeded with Escherichia coli OP50. All strains were outcrossed at least four
times, with the exception of SJ4100, which was outcrossed three times. The
outcrossed prdx-2(gk169) and acdh-1(ok1489) strains were renamed LSC555
and LSC556, respectively. All experiments were performed at 20 °C unless
stated otherwise.
Fig. 6. The mitohormetic signaling cascade as induced by metformin.
Metformin induces an increase in activity in several catabolic pathways (Fig.
S6), including the TCA cycle and β-oxidation, with β-oxidation producing
a relatively higher amount of FADH2 per cycle. This increase in substrate
allows for an increase in mitochondrial respiration, which in turn leads to an
increase in ROS production, possibly through metformin-mediated pertur-
bation of electron transport (marked in red). These ROS oxidize PRDX-2
peroxiredoxins, which subsequently dimerize and enter their active state.
Active PRDX-2 will activate a conserved MAPK cascade containing the p38
MAPK PMK-1, likely leading to the activation of SKN-1 (28) and a concomi-
tant increase in longevity and stress protection (dashed arrows: literature-
based evidence; Fig. S6 provides more information on the pathways induced
by metformin treatment).
E2506 | www.pnas.org/cgi/doi/10.1073/pnas.1321776111 De Haes et al.
Sampling for Two-Dimensional Difference Gel Electrophoresis. The protein
samples for two-dimensional difference gel electrophoresis (2D-DIGE) were
taken from glp-4(bn2ts) daf-16(mgDf50)worms grown in liquid cultures. The
glp-4(bn2ts) mutation confers sterility at the permissive temperature of 24 °C,
avoiding contamination with progeny. Preventing germ-line development
also removes abundant contaminating proteins that have no bearing on
lifespan, facilitating the analyses. Because glp-4 mutations cause a slight DAF-
16–dependent lifespan increase in C. elegans cultured on dead E. coli (57), glp-
4(bn2ts) daf-16(mgDf50) double mutants were used. This does not interfere
with the envisaged results, because lifespan extension due to metformin is
independent of DAF-16 (5). Cultivating the worms in liquid cultures allowed
full control over metformin dosage while ensuring that all worms were fully
fed. Additionally, the high-density samples obtained from liquid cultures en-
sure high protein concentration in 2D-DIGE experiments.
Worms were synchronized by isolating eggs from gravid adults through
hypochlorite and NaOH treatments (58) and a subsequent sucrose density
centrifugation to separate eggs from dead worms and bacterial debris. L1
worms were added to Fernbach flasks containing S medium (59) and con-
stantly shaken at 24 °C. Flash frozen E. coli K12 bacteria (Artechno) were
added to the cultures as food source. The concentration of bacteria was
checked twice daily, and new K12 bacteria were added accordingly to
maintain the cultures at optimal food levels (OD550 = 1.8). The density of
worms in the culture never exceeded 1,000 worms/mL to prevent large
fluctuations in food availability. When worms reached the L4 stage, cultures
were supplemented with 2′-deoxy-5-fluorouridine (FUdR; Sigma-Aldrich) at
a final concentration of 100 mg/L. This ensures complete sterility, because
glp-4(bn2ts) daf-16(mgDf50) worms rarely manage to produce a few eggs.
Once worms reached the adult stage, the test group was exposed to 25 mM
of metformin (1,1-dimethylbiguanide hydrochloride; Sigma-Aldrich) for 24 h
(SI Materials and Methods describes the determination of the optimal
metformin concentration in liquid media; Fig. S7), and protein samples were
subsequently taken (SI Materials and Methods provides a complete protocol
on protein extraction).
2D-DIGE. Samples were labeled, separated, and analyzed as described by
Bogaerts et al. (60). In short, metformin-treated and nontreated protein
extracts were differentially labeled with either Cy3 or Cy5 fluorescent dyes
(GE Healthcare). A possible dye bias was taken into account by integrating
a dye swap into the experimental design. Differentially labeled samples
were pooled, an internal standard labeled with Cy2 was added, and the
pooled samples were separated in two dimensions. Gels were scanned using
an Ettan DIGE Imager (GE Healthcare), and DeCyder 7.0 (GE Healthcare) was
used to statistically analyze the images. Spot intensity was compared using
a standard Student t test with false positive rate correction.
Trypsin Digestion and Identification of Differential Proteins. Differential spots
were excised using an automated spotpicker (GE Healthcare). The proteins in
each spot were digested using a standard in-gel trypsin digestion protocol
and subsequently identified using peptide mass fingerprinting (SI Materials
and Methods provides a complete protocol).
Clustering of Differential Proteins.Wormbase gene IDs of differential proteins
were uploaded to the bioinformatic tool DAVID (23) to look for enrichment
in functional clusters. Functional clustering was performed with high strin-
gency. Pathway enrichment was determined using DAVID by querying the
Kyoto Encyclopedia of Genes and Genomes.
Lifespan Experiments. All lifespan experiments were performed on NGM agar
plates or NGM plates supplemented with or without 50 mM of metformin.
NAC was used at a concentration of 5 mM and BHA at a concentration of
25 μM, when applicable. For the experiment using BHA, the compound was
added from a 1,000× concentrated stock in DMSO, and an equal volume of
DMSO was added to the respective controls. The worms used in the BHA
lifespan experiment were pretreated with 25 μM of BHA for one generation
before the start of the experiment. For lifespan experiments, 20 L4 stage
worms from a synchronous culture were transferred to a plate (either reg-
ular NGM or NGM containing one or multiple of the tested compounds),
allowed to lay eggs for 24 h, and were then removed from the plate. The
progeny was transferred to a new plate when they reached the young adult
stage and were transferred to new plates during each day of their re-
productive period and every 3 d thereafter. Lifespan was monitored every
day starting from day 1 of the adult stage: animals that did not move when
gently prodded were marked as dead. Animals that crawled off the plate or
died of vulval bursting or internal hatching were censored. Survival curves
were statistically analyzed using a Cox proportional hazard (to compare the
effect of metformin between strains and/or conditions) or log–rank test (to
compare a single curve to control; corrected for multiple testing using the
Benjamini-Hochberg method). Complete information regarding lifespan
experiments can be found in the SI (Table S1).
Measuring hsp-6::GFP Fluorescence. Synchronized L1 worms of the SJ4100
zcIs13[hsp-6::GFP] strain were transferred to agar plates containing 0 mM,
50 mM, or 100 mM of added metformin. As a positive control, worms were
transferred to plates seeded with HT115 Escherichia coli containing an RNAi
construct targeted against cco-1 (24). To rule out a specific effect of HT115,
plates seeded with HT115 containing an empty vector were used, which
caused no fluorescence. Images were acquired using a Zeiss Axio Imager
Z1 microscope.
Measuring Metabolic Heat and Respiration. Metabolic activity and respiration
measurements were carried out as previously described (61). In short, res-
piration and metabolic heat production of synchronized day-1 adult worms
were measured using a Clark-type electrode respirometer (Strathkelvin) and
a Thermal Activity Monitor (Thermometric), respectively. Treated worms
were exposed to 50 mM metformin starting from the L1 stage. Oxygen
consumption rates were measured over a span of 15 min. After thermal
equilibration of the calorimeter, live heat output of each sample was av-
eraged over a 3-h period. All data were normalized according to the
protein concentration in each sample, because this directly correlates to
worm biomass. Protein concentrations were determined using a bicincho-
ninic acid kit (Thermo Scientific). Student t tests were used to statistically
analyze the data.
Quantifying in Vivo Hydrogen Peroxide Production. Endogenous hydrogen
peroxide production was quantified using the Amplex Red hydrogen per-
oxide kit (Invitrogen, catalog no. A22188). Adult worms were washed three
times with S basal (59), after which the worms were pelleted through cen-
trifugation (800 × g, 3 min). From this dense pellet, 50 μL of worms were
transferred to a new microcentrifuge tube containing 450 μL of reaction
buffer (sodium phosphate buffer supplied with the kit). After centrifugation
(800 × g, 1.5 min), the reaction buffer was replaced with fresh reaction
buffer, and 500 μL of Amplex Red working solution (prepared according to
the manufacturer’s instructions) was added. The worms were allowed to
rotate in the dark for 1 h, after which they were pelleted through centri-
fugation (800 × g, 1.5 min), and 100 μL of supernatant was transferred to a
fluorescence-compatible 96-well plate. Fluorescence (Ex 550 nm, Em 590 nm)
was measured, and the worm pellet was subjected to protein extraction for
normalization. Welch’s t tests with multiple testing correction (Benjamini-
Hochberg) were used to statistically analyze the heteroscedastic data.
Measuring Mitochondrial Respiration. Mitochondria were extracted from
worms as previously described (62). Oxygen consumption of the extracted
mitochondria was determined using a Clark-type electrode (Oxygraph 2k)
and DatLab software (Oroboros Instruments). An aliquot of 25 μL of mito-
chondria was incubated in 2 mL of air-saturated MiR05 (0.5 mM EGTA, 3 mM
MgCl2, 60 mM K-lactobionate, 20 mM taurine, 10 mM KH2PO4, 20 mM Hepes,
110 mM sucrose, and 1 g/L BSA, pH 7.1) at 20 °C. The effect of 25 mM of
metformin on electron transport from complex I and complex II was mea-
sured as follows: (i) metformin was added from a 1.5-M stock (dissolved in
MiR05) until a final concentration of 25 mM was reached; (ii) the complex I
substrates pyruvate and malate were added from a 1-M stock until a final
concentration of 5 mM was reached; (iii) ADP was added from a 10-mM
stock to initiate complex I respiration (final concentration 25 μM); (iv) when
applicable, rotenone was added as a positive control at a final concentration
of 1 μg/mL from a 400-μg/mL stock; (v) to initiate complex II respiration,
succinate was added from a 1-M stock until a final concentration of 5 mM
was reached.
Measuring Mitochondrial Hydrogen Peroxide Production. Mitochondrial hy-
drogen peroxide production was quantified using a protocol based on the
Amplex Red hydrogen peroxide kit (Invitrogen, catalog no. A22188). A
fluorescence-compatible 96-well plate was prepared, and several wells were
filled with 96 μL of incubation medium (4 mM ADP, 10 mM pyruvate, 10 mM
malate, 10 U Cu/ZnSOD) either containing no additional substance, 25 mM
of metformin, or 1 μg/mL of rotenone. Subsequently, 100 μL of Amplex Red
reaction buffer (100 μM Amplex Red, 4 U/mL horseradish peroxidase dis-
solved in the sodium phosphate buffer supplied with the kit) was added,
followed by the addition of 4 μL of freshly extracted mitochondria. The plate
was shaken in the dark, and every 2 min fluorescence (Ex 550 nm, Em 590 nm)
was measured over the span of 1 h to accurately plot the increase in fluorescence
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over time resulting from hydrogen peroxide production. The resulting
curves were statistically analyzed using analysis of covariance.
Anti-PRDX-2 Western Blot. A nonreducing anti-PRDX-2 Western blot was
performed as described by Oláhová et al. (45). In short, synchronized L1
worms were grown on NGM plates with or without 50 mM of added met-
formin. Proteins were extracted from young adult worms and separated on
a nonreducing SDS/PAGE gel. Rabbit anti-PRDX-2 antibodies were kindly
provided by Elizabeth Veal (Newcastle University, Newcastle upon Tyne, UK).
Intensity of PRDX-2 bands was normalized against total protein content of
each lane, which was visualized using a Deep Purple (GE Healthcare) total
protein stain. A Welch’s t test was performed to analyze the data.
Anti Phospho-PMK-1 Western Blot. N2 and prdx-2 worms were synchronized
and grown on regular NGM plates. Protein samples of day-1 adult worms
were taken as described for the 2D-DIGE experiment. Proteins were sepa-
rated on an SDS/PAGE gel, and rabbit anti-phospho-p38 antibodies were
used for visualization (Cell Signaling Technology). Blots were reincubated
with rabbit anti-histone H3 antibodies (Abcam) as a loading control (63).
Measuring Fat Content Through Oil Red O Staining. Synchronized L1 worms
were cultivated on NGM plates with or without 50 mM of added metformin.
L4 stage worms were harvested and stained with Oil red O. The staining
intensity was acquired for at least 30 worms for each condition (SI Materials
and Methods). A Student t test was performed to analyze the data.
Measuring Worm Volume. Wild-type worms were synchronized through hy-
pochlorite treatment, and L1 worms were transferred to normal NGM plates
or NGM plates supplemented with 50 mM of metformin. FUdR was added
to the plates when worms reached the L4 stage at a final concentration of
50 μM. For sampling, worms were washed twice with S basal and subsequently
fixed in 4% (wt/vol) formaldehyde (3 min at 65 °C). Images of the formal-
dehyde fixed worms were captured, and worm width (D) and length (L) were
analyzed using a RapidVUE Particle Shape and Size Analyzer (Beckman
Coulter). Worm volume was approximated using the cylinder formula
[V = πL(D/2)2].
Electron Micrographs. Wild-type worms were synchronized and sterilized as
described for the volume measurements. Worms were harvested when they
reached day 9 of adulthood and prepared for electronmicroscopy (SI Materials
and Methods).
Quantifying Concentration of BCAAs. Wild-type worms were synchronized, and
L4 worms were harvested from the plates. BCAA concentration was measured
using a BCAA assay kit (Sigma-Aldrich, catalog no. MAK003) according to man-
ufacturer’s instructions. Total protein content of the extracts was quantified using
the Qubit Protein Assay (Invitrogen) and used for normalization. A Welch’s t test
was performed to analyze the data.
Statistical Analysis. All statistical analyses, apart from the DeCyder and DAVID
analysis, were carried out using R (64). All bar graphs show the mean of bi-
ologically independent samples, and error bars show SEM. P values <0.05 were
considered significant.
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SI Materials and Methods
Protein Extraction for Two-Dimensional Difference Gel Electrophoresis.
Worms were pelleted through centrifugation and washed trice
with an isotonic 0.1-M NaCl solution. Live worms were separated
from dead worms and remaining bacteria via a density centri-
fugation step using 30% (vol/vol) sucrose: living worms float on
top, whereas dead worms and bacteria pellet out in the sucrose.
The live worms were washed three times with an isotonic 0.1-M
NaCl solution. The final pellet was added to cold lysis buffer
[7 M ureum, 2M thioureum, 1%DTT, 4% (wt/vol) CHAPS, and
40 mM Tris supplemented with Roche Complete Protease In-
hibitor], homogenized, and put on ice. Next, the homogenate was
briefly sonicated and then centrifuged for 12min at 16,000× g (4 °C).
Supernatants were desalted overnight at 4 °C using the PlusOne
Mini Dialysis Kit (GEHealthcare). Finally, protein concentration in
each sample was determined using the Qubit Protein Assay (In-
vitrogen), and samples were stored at −80 °C until further use.
Trypsin Digestion and Protein Identification.Differential spots were
excised using an automated spotpicker (GE Healthcare). Gel
plugs were washed with 200 μL ultrapure water for 15 min and
subsequently dehydrated by treating them twice with 200 μL 50%
(vol/vol) acetonitrile for 15 min. Next the plugs were rehydrated
by washing them twice with 100 μL ultrapure water for 5 min.
This was followed by a complete dehydration step, in which plugs
were submerged in 100 μL 100% (vol/vol) acetonitrile. When the
gel plugs were completely white and dehydrated the acetonitrile
was removed, and the plugs were allowed to air dry for 10 min.
Next, 50 μL of cold digestion buffer [25 mM ammonium car-
bonate, 5% (vol/vol) acetonitrile] containing 100 ng of se-
quencing grade modified trypsin (Promega) was added, and the
plugs were allowed to swell again at 4 °C. After 30 min we
checked whether the gel plugs were still submerged completely
and added additional digestion buffer if this was not the case.
The plugs were allowed to incubate for 1 additional hour at 4 °C,
after which they were incubated at 37 °C overnight. The next day,
100 μL of the first extraction solution [5% (vol/vol) acetonitrile,
5% (vol/vol) formic acid] was added to the digestion buffer, and
the plugs were incubated for another 15 min at 37 °C. The so-
lution surrounding a plug, containing the tryptic peptides, was
removed and collected in a collection tube. The plugs were re-
submerged in 50 μL of the second extraction solution [50%
(vol/vol) acetonitrile, 5% (vol/vol) formic acid] and allowed to in-
cubate at 37 °C for 15 s. This solution was added to the same
collection tube. The tryptic peptides in each tube were dried
using a SpeedVac concentrator (Savant) and subsequently de-
salted using ZipTip pipette tips (Millipore).
Mass spectrometry was performed on an Ultraflex II MALDI-
TOF mass spectrometer (Bruker Daltonics) operated in reflectron
positive ion mode. For each spot, 1 μL of tryptic peptides and 1 μL
of matrix [saturating amount of α-cyano-4-hydroxycinnamicacid
dissolved in 50% (vol/vol) acetone] were spotted on a ground
steel MALDI plate (Bruker Daltonics) and allowed to air dry.
For each spot, the signal of 3,000 laser shots was added. The
instrument was calibrated using peptide calibration standard II
(Bruker Daltonics). Differential proteins were identified through
peptide mass fingerprinting using Mascot (Matrix Science). A
mass tolerance of 0.2 Da was used in all searches, and we al-
lowed one missed cleavage per peptide. Carbamidomethylation
(C) and oxidation (M) were selected as fixed and variable
modifications, respectively. Additionally, all searches were limited
to Caenorhabditis elegans proteins. We searched the annotated
and reviewed SwissProt database for potential identifications. If
no clear hit emerged, we additionally searched the general
National Center for Biotechnology Information database, because
this database contains more sequences (albeit some nonreviewed).
Determining Optimal Concentration of Metformin in Liquid Media.
The optimal concentration of metformin in liquid media was
determined using a protocol based on the fluorescent dye SYTOX
green (Invitrogen). When binding to DNA, SYTOX green emits
a green fluorescent signal. However, the dye can only enter cells
when their membrane is compromised, thus making it an ideal
marker for dead worms (1). In short, worms were synchronized
by treating gravid adults with hypochlorite and NaOH. After
hatching, L1 worms were transferred to Fernbach flasks con-
taining S medium (2) supplemented with different concen-
trations of metformin (100 mM, 50 mM, 25 mM, 12.5 mM, 6.25
mM, 0 mM) and constantly shaken. Flash frozen K12 Escherichia
coli bacteria (Artechno) were added to the cultures as food
source until an optimal concentration was reached (OD550 =
1.8). The concentration of bacteria was checked twice daily, and
new K12 bacteria were added to maintain the cultures at optimal
food levels. When worms reached the L4 stage, cultures were
supplemented with 2′-deoxy-5-fluorouridine (Sigma-Aldrich) to
prevent the formation of progeny (final concentration, 100 mg/L).
Once the worms reached the adult stage, samples were taken
daily: 190 μL of a worm culture was added to a 96-well plate and
mixed with 10 μL of a 20 μM SYTOX green stock solution. After
incubating the well plate for 15 min in the dark, dead and living
worms were counted using a Leica MZ16F fluorescence micro-
scope. Survival curves were statistically analyzed using a general-
ized linear model (binomial).
Oil Red O Staining. Worms were fixed in 1× Modified Ruvkun’s
Witches Brew (MRWB) containing 2% (wt/vol) formaldehyde
[made from a 2× MRWB stock: 160 mM KCl, 40 mM NaCl, 20
mM EGTA, 10 mM spermidine, 30 mM Pipes (pH 7.4), and 50%
(vol/vol) methanol]. After 1 h, fixed worms were pelleted
through centrifugation and washed with S basal. Worms were
subsequently incubated for 15 min in a 60% (vol/vol) iso-
propanol solution, after which the isopropanol solution was re-
placed with Oil-red O solution [0.3% Oil-red O in 60% (vol/vol)
isopropanol]. Worms were rotated in the Oil-red O solution
overnight, in the dark. Finally, the stained worms were washed
three times with S basal, and bright-field images of the worms
were acquired using a Zeiss Axio Imager Z1 microscope. The
red component of the Oil-red O images was converted to gray-
scale and subsequently analyzed using ImageJ. The intensity of
Oil-red O staining in each image was acquired using a stan-
dardized threshold and normalized against the area of each
worm. At least 30 worms were measured for each condition. A
Student t test was performed to statistically analyze the data.
Electron Micrographs. Nine-day-old adult worms were washed 3
times with 0.1 M NaCl. Worms were subsequently fixed, first in
cold 2% (vol/vol) glutaraldehyde, buffered at pH 7.3 with 50 mM
Na-cacodylate and 150 mM saccharose, followed by fixation in
2% (wt/vol) osmium tetroxide. Fixed worms were dehydrated in
an acetone series and embedded in araldite. Semithin sections of
1 μm cut with a Reichert Ultracut E microtome were stained with
methylene blue and viewed in a Zeiss Axioskop light microscope.
Double-stained 70-nm thin sections were visualized using a Zeiss
EM90 electron microscope.
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Fig. S1. Metformin treatment does not induce the mitochondria-specific unfolded protein response. Metformin-treated hsp-6::GFP worms show no difference
in fluorescence compared with untreated control worms, both at the optimal concentration of 50 mM and at a higher concentration (100 mM), indicating that
metformin-mediated lifespan extension via the induction of the UPRmt is highly unlikely. hsp-6::GFP worms were exposed to cco-1 RNAi as a positive control,
which resulted in a marked increase in fluorescence, especially after the L4 stage. cco-1 encodes a cytochrome c oxidase subunit, an integral part of the
mitochondrial electron transport chain (1).
1. Durieux J, Wolff S, Dillin A (2011) The cell-non-autonomous nature of electron transport chain-mediated longevity. Cell 144(1):79–91.
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Fig. S2. Diverse lifespan experiments. (A) Treatment with the fat-soluble antioxidant butylated hydroxyanisole (BHA) abolishes the lifespan extending effect
of metformin (***P < 0.001; n ≥ 97 for each curve; Table S1). (B) Metformin exposure restricted to adulthood or to the first 5 d of adulthood is sufficient to
extend lifespan (***P < 0.001 for both). Limiting metformin exposure to the larval stages had no significant effect on longevity (n.s.P > 0.05; n ≥ 92 for each
curve; Table S1). (C) The antioxidant N-acetylcysteine (NAC) partially rescues the debilitating effect of metformin on prdx-2 knockout worms (***P < 0.001; n ≥
90 for each curve; Table S1).
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Fig. S3. Metformin treatment induces formation of PRDX-2 dimers. Nonreducing Western blot was performed to quantify the amount of oxidized PRDX-2
dimers after metformin treatment (50 mM). Band intensity was normalized against total protein content in each lane and plotted in a bar graph. The nor-
malization factor is acquired by referencing the amount of protein in the first lane to the total protein ratio for each other lane. The bar graph shown is the
same graph as Fig. 2E in the main text. Bars represent mean ± SEM (n = 4).
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Fig. S4. Metformin inhibits complex I of the mitochondrial electron transport chain (ETC). (A) Metformin and rotenone inhibit complex I- but not complex
II-based respiration. The effect of metformin on mitochondrial respiration was measured by sequentially adding compounds to stimulate different parts of the
ETC. A positive O2 flux indicates the use of oxygen by mitochondrial respiration, with higher values indicating higher respiration, negative values indicating
a small influx of O2, usually due to the injection of a compound. Green arrows indicate compounds that were added in both the control and metformin-treated
cell; red and black arrows indicate compounds that were only added in the treated or control cell respectively. After adding an equal volume of mitochondria
(↓start), metformin was added to one of the cells (↓metformin). Subsequently, the complex I substrates pyruvate and malate (↓P+M) were added, followed by
the addition of ADP (↓ADP), thus initiating electron transport from complex I. In the control cell respiration clearly increased, whereas the metformin-treated
mitochondria failed to initiate complex I-based respiration, thus indicating that metformin inhibits electron transport from complex I in vitro. Because of the
higher concentration of mitochondria and a resultant depletion of substrates, this peak was more transient than in Fig. 3A. Subsequently, we inhibited
complex I-based respiration in the control cell using rotenone (↓rotenone), resulting in a drop in respiration to the baseline. Finally, the complex II substrate
succinate (↓S) was added to both cells, which led to a marked increase in mitochondrial respiration, thus indicating that metformin and rotenone did not block
electron transport from complex II. (B) Similar setup as previously described, except no rotenone was added and succinate (↓S) was added to both cells, re-
vealing a cumulative effect of complex I and II respiration in the control cell.
Fig. S5. Metformin treatment induces the branched-chain amino acid (BCAA) degradation pathway. The BCAA degradation pathway, based on the BCAA
pathway from the Kyoto Encyclopedia of Genes and Genomes. Enzymes noted in red are up-regulated after metformin treatment. The same enzymes are used
in the first steps of the degradation of each BCAA (dashed line).
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Fig. S6. Putative mode of action for metformin-mediated lifespan increase. Scheme summarizing the different effects of metformin in C. elegans. Blue lines
represent a negative or inhibitory effect; red lines represent positive or stimulatory effect. The direct effect of metformin is thoroughly described in this article.
For more information about the bacteria-specific effect of metformin, see Cabreiro et al. (1). In summary, metformin inhibits complex I of the ETC in a way
distinct from the classic complex I inhibitor rotenone, causing increased ROS production. This inhibition leads to a decrease in ATP levels and a resultant
activation of AMPK, leading to an increase in catabolism and respiration, which in turn exacerbates the metformin-mediated production of ROS. The increased
production of ROS activates the mitohormetic pathway through oxidation of PRDX-2 (Fig. 6 gives more detail on the metformin-mediated induction of mi-
tohormesis). Simultaneously, an increase in activity in the BCAA degradation pathway causes a reduction in BCAA (leucine, valine, and isoleucine) concen-
tration. It is, however, unknown how metformin is able to induce increased BCAA degradation. To our knowledge, there is no evidence of AMPK as being
directly involved in BCAA degradation. Present knowledge of the BCAA degradation pathway in mammals indicates that it is mainly activated by the group of
peroxisome proliferator-activated receptors, which in turn are activated by free fatty acids and other fatty acid derivatives (2). Because AMPK activates lipases
in adipose tissues and thus increases the concentration of these free fatty acid ligands (3), the kinase may yet be indirectly involved in the activation of the
BCAA degradation pathway. We speculate that this activation leads to reduced protein translation both indirectly through inhibition of TOR and directly
through a reduction of substrate available for protein translation. The combination of mitohormesis and reduced protein translation adds to an increased
healthspan.
1. Cabreiro F, et al. (2013) Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell 153(1):228–239.
2. Harris RA, Joshi M, Jeoung NH (2004) Mechanisms responsible for regulation of branched-chain amino acid catabolism. Biochem Biophys Res Commun 313(2):391–396.
3. Kahn BB, Alquier T, Carling D, Hardie DG (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1(1):15–25.
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Fig. S7. Effect of metformin on C. elegans lifespan in liquid media. Graph showing the mean lifespan of C. elegans in liquid media after treatment
with different concentrations of metformin. Lifespan extension reached an optimum at 25 mM of metformin (***P < 0.001). Bars represent mean life
span ± SEM.
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Table S1. Summary of performed lifespan experiments
Condition N # Mean LS ± SEM
Effect of
metformin (%) pLogRank pCOXPH
Experimental group 1: control vs. prdx-2 and NAC
N2 172 10 12.79 0.43 30.57 1.48E-9*** NA
N2 Met 169 10 16.70 0.40
prdx-2 139 10 10.61 0.40 −36.27 6.00E-16*** < 2E-16***
prdx-2 Met 127 10 6.76 0.18
N2 NAC 171 10 13.17 0.49 5.54 0.419 ns 6.40E-4***
N2 NAC + Met 171 10 13.90 0.48
Experimental group 2: control DMSO vs. BHA
N2 DMSO 99 5 11.99 0.55 40.78 2.48E-09 NA
N2 DMSO + Met 97 5 16.88 0.45
N2 BHA 99 5 12.52 0.64 −0.005 0.898 ns 7.54E-5***
N2 BHA + Met 101 5 12.45 0.54
Experimental group 3: metformin timings
N2 97 5 12.65 0.63 NA NA NA
N2 Met 92 5 18.65 0.58 47.43 3.95E-9*** NA
N2 Met adult 102 5 19.90 0.57 57.31 1.22E-12*** NA
N2 Met 5 d 98 5 18.21 0.63 43.95 3.95E-9*** NA
N2 Met larval 99 5 12.06 0.60 −0.046 0.502 ns NA
Experimental group 4: NAC and prdx-2 interaction
prdx-2 90 5 8.79 0.30 −27.19 2.62E-11*** NA
prdx-2 Met 99 5 6.40 0.17
prdx-2 NAC 98 5 8.49 0.45 −8.95 0.084 ns 2.15E-5***
prdx-2 NAC+Met 98 5 7.73 0.38
Experimental group 5: control vs. acdh-1
N2 75 5 12.95 0.60 13.67 0.013* NA
N2 Met 77 5 15.00 0.49
acdh-1 85 5 9.03 0.41 76.52 7.33E-10*** 8.21E-9***
acdh-1 Met 54 5 15.94 0.86
The total amount of tested worms (N), the number of independent experiments (#), the mean lifespan (mean
LS with error), and the increase in mean lifespan due to metformin treatment are shown for each tested strain
or condition. Both log–rank and Cox proportional hazard tests were performed to determine statistical signif-
icance. pLogRank is the P value of the log–rank test used to compare survival between treated and nontreated
worms within a single strain, corrected for multiple testing (Benjamini-Hochberg). pCOXPH is the P value of the
Cox proportional hazard test used to determine whether the effect of metformin was different from the effect
of metformin on the control. ns, not significant; *P < 0.05; ***P < 0.001.
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